Anti-Mullerian Hormone Dosing for Oocyte Yield and Follicle Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current understanding of anti-Müllerian hormone (AMH) mechanisms in follicular development is limited, and there is a need for effective treatments for impaired follicular development and infertility, particularly in conditions like diminished ovarian reserve and polycystic ovary syndrome (PCOS).

Innovation Solution

Administration of AMH at specific doses and durations, combined with modulators of miR-181a and miR-181b, to regulate folliculogenesis and fertility treatments, including formulations with surfactants, buffers, and pH control for stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If AMH is administered to treat infertility and regulate folliculogenesis, then follicle development is stabilized and oocyte collection increases, but the mechanism of action is not fully understood and treatment optimization is limited

Engineering Contradiction:

Improvenumber of collected oocytesVSAvoidunderstanding of AMH mechanisms

Core Design Contradiction:

ProductivityVSLoss of information

Solution Approach 1:

The patent employs feedback mechanisms by monitoring follicle development stages and AMH levels to optimize treatment dosing and duration, allowing dynamic adjustment of therapy based on patient response and mechanistic understanding

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent applies preliminary action by administering AMH before superovulation induction to pre-condition the ovarian follicles, thereby enhancing their responsiveness to subsequent stimulation protocols and improving oocyte yield

Inventive Principle:

Principle #10Preliminary action

2Reliability

If AMH administration is used to treat diminished ovarian reserve, then follicle loss is reduced, but excessive AMH may cause follicular arrest and impaired ovulation

Engineering Contradiction:

Improvefollicle retention in diminished ovarian reserveVSAvoidfollicular arrest and impaired ovulation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by carefully controlling AMH dosage, administration duration, and timing relative to the menstrual cycle to achieve therapeutic effects while avoiding follicular arrest and maintaining normal ovulation function

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses partial action by administering sub-physiological doses of AMH that are sufficient to protect follicles in diminished ovarian reserve but insufficient to cause complete follicular arrest, thereby balancing protection with maintained fertility function

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentUS10478473B2Compositions and methods of using anti-mullerian hormone for treatment of infertility

Publication Date: 2019.11.19 CENT FOR HUMAN REPRODN

AI summary

The present invention provides compositions and methods for the treatment of subjects with impaired fertility or at risk for impaired fertility. In certain aspects, the invention relates to increasing the level or activity of anti-Mullerian hormone (AMH) in a subject.